Metrikler
Yayın
61
Açık Erişim
15
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2011 - 2013
2011 - 2013Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Medikal Onkoloji Bilim Dalı, Türkiye
2004 - 2010
2004 - 2010Tıpta Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, Türkiye
1997 - 2004
1997 - 2004Lisans
Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Türkiye
Yaptığı Tezler
2013
2013Tıpta Uzmanlık
HACETTEPE ÜNİVERSİTESİ HASTANELERİ’NDE TAKİP EDİLEN METASTATİK RENAL HÜCRELİ KANSER HASTALARININ SAĞKALIMLARININ ZAMAN İÇİNDE DEĞİŞİMİNİN İNCELENMESİ
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Medikal Onkoloji
2010
2010Tıpta Uzmanlık
ZOLEDRONİK ASİDİN RATLARDA DOKU SDF-1 EKSPRESYONU ÜZERİNDEKİ ETKİSİ
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları
Yabancı Diller
B2 Orta Üstü
B2 Orta Üstüİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2017 - Devam Ediyor
2017 - Devam EdiyorDoç. Dr.
Hacettepe Üniversitesi, Tıp Fakültesi (Türkçe), Dahili Tıp Bilimleri Bölümü
Akademi Dışı Deneyim
2017 - 2017
2017 - 2017Uzman Doktor
SAĞLIK BAKANLIĞI ESKİŞEHİR YUNUS EMRE DEVLET HASTANESİ, Uzman Doktor
2013 - 2017
2013 - 2017Tıbbi Onkoloji Uzman Doktoru
Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Uzman Doktoru
Makaleler
Tümü (44)
SCI-E, SSCI, AHCI (36)
SCI-E, SSCI, AHCI, ESCI (42)
ESCI (6)
Scopus (38)
TRDizin (8)
2025
20251. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer
YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica
, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
2025
20252. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
, sa.4, ss.129-137, 2025 (SCI-Expanded)
2025
20253. The association between HALP score and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.1, ss.81-89, 2025 (SCI-Expanded)
2024
20244. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
20245. Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study
On S., KÖKSAL B., ARIK Z., Caner B., ERCAN UZUNDAL D., YAZICI O., et al.
CURRENT ONCOLOGY
, cilt.31, sa.11, ss.6803-6813, 2024 (SCI-Expanded, Scopus)
2024
20246. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
, cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus)
2024
20247. Erken Evre Serviks Kanseri Hastalarında Progresyonun Öngördürücüsü Olarak Nötrofil Lenfosit Oranı
Akyıldız A., Ismayilov R., Arık Z.
Journal of medicine and palliative care (Online)
, cilt.5, sa.4, ss.203-207, 2024 (TRDizin)
2024
20248. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.
BIOMOLECULES AND BIOMEDICINE
, cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)
2024
20249. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., et al.
Future oncology (London, England)
, cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)
2024
202410. Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report
KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.
PLASMATOLOGY
, cilt.18, 2024 (ESCI, Scopus)
2024
202411. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]
Seoud M., Ladjeroud A., Jaafar H., Mokhtar M., Ozyilkan O., Alkhayyat S., et al.
Current Women's Health Reviews
, cilt.20, sa.1, 2024 (ESCI, Scopus)
2023
202312. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology
, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
2023
202313. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine
, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)
2023
202314. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202315. Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience
Yilmaz M., Başak M., Özyükseler D. T., Yildirim M. E., ARIK Z., SALMAN M. C., et al.
Turk Onkoloji Dergisi
, cilt.38, sa.3, ss.323-332, 2023 (ESCI, Scopus, TRDizin)
2023
202316. Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System
ERDAT E. C., ARIK Z., BARIŞTA İ.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, cilt.33, sa.3, ss.170-178, 2023 (SCI-Expanded, Scopus, TRDizin)
2023
202317. Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature
KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.
Corrosion Science and Technology
, cilt.19, sa.3, ss.184-189, 2023 (ESCI, Scopus)
2022
202218. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus)
2022
202219. The impact of COVID-19 pandemic on nosocomial multidrug-resistant bacterial bloodstream infections and antibiotic consumption in a tertiary care hospital
Metan G., Cuha M. D., Hazirolan G., Dizman G., Tanriverdi E. S., Otlu B., et al.
GMS HYGIENE AND INFECTION CONTROL
, cilt.17, 2022 (ESCI)
2022
202220. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia
Korkmaz V., Sunar V., Akar S., Alinca C. M., ARIK Z., Boran N., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
, cilt.18, sa.3, ss.326-332, 2022 (SCI-Expanded, Scopus)
2022
202221. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer
Sunar V., Korkmaz V., Topcu V., Cavdarli B., ARIK Z., Ozdal B., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
, cilt.18, sa.1, ss.84-92, 2022 (SCI-Expanded, Scopus)
2022
202222. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202223. Ovarian Carcinoma Presenting With a Large Cervical Mass
YILMAZ M. T., GÜRLEK E., GÜLTEKİN M., Kahraman K., SALMAN M. C., USUBÜTÜN A., et al.
CUREUS JOURNAL OF MEDICAL SCIENCE
, cilt.14, sa.1, 2022 (ESCI)
2022
202224. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment
GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.
ANTI-CANCER DRUGS
, cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)
2021
202125. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202126. Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?
ARIK Z., ERMAN M.
JOURNAL OF THORACIC ONCOLOGY
, cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)
2021
202127. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202128. The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer
Lacin S., TAŞAR KAPAKLI G. E., USUBÜTÜN A., ARIK Z., YÜCE D., SALMAN M. C., et al.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
, cilt.42, sa.3, ss.541-547, 2021 (SCI-Expanded, Scopus)
2021
202129. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging
GÜLTEKİN M., Guler O. C., Sari S., Yildirim B. A., Onal C., Celik H., et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY
, cilt.41, sa.3, ss.414-420, 2021 (SCI-Expanded, Scopus)
2021
202130. Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)
GÜLTEKİN M., AK S., AYHAN A., Strojna A., Pletnev A., Fagotti A., et al.
CANCER MEDICINE
, cilt.10, sa.1, ss.208-219, 2021 (SCI-Expanded, Scopus)
2021
202131. Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer
Sunar V., Korkmaz V., Aslan K., Kose C., Sarici F., ARIK Z., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.4, ss.239-245, 2021 (SCI-Expanded, Scopus, TRDizin)
2020
202032. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER
, cilt.19, sa.3, 2020 (SCI-Expanded, Scopus)
2019
201933. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.
JOURNAL OF BUON
, cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)
2019
201934. Retrospective Analysis of Gestational Trophoblastic Neoplasia: Single Center Experience
Sunar V., Korkmaz V., ARIK Z., Ozdal B., Engin Ustun Y.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.29, sa.3, ss.168-175, 2019 (SCI-Expanded, Scopus, TRDizin)
2016
201635. Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer
Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E., OZGU E., TERZIOGLU S. G., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.2, ss.110-115, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
201536. Molecular subtypes in patients with inflammatory breast cancer; A single center experience
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus)
2015
201537. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature
Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.348, 2015 (SCI-Expanded, Scopus)
2014
201438. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"
Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., et al.
WIENER KLINISCHE WOCHENSCHRIFT
, cilt.126, ss.36-41, 2014 (SCI-Expanded, Scopus)
2013
201339. Association between common risk factors and molecular subtypes in breast cancer patients
Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.
BREAST
, cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded, Scopus)
2012
201240. Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use
Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Ozdemir N. Y., Zengin N., et al.
MEDICAL ONCOLOGY
, cilt.29, sa.4, ss.2601-2605, 2012 (SCI-Expanded, Scopus)
2012
201241. Dermatomyositis complicated with a soft tissue sarcoma
Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Kilinc L., Zengin N.
RHEUMATOLOGY INTERNATIONAL
, cilt.32, sa.10, ss.3329-3330, 2012 (SCI-Expanded, Scopus)
2012
201242. Can all beta blockers improve the breast cancer survival?
Sendur M. A. N., Aksor S., Yaman S., Arik Z., Altundag K.
BREAST
, cilt.21, sa.1, ss.107-108, 2012 (SCI-Expanded, Scopus)
2012
201243. Is There an Association between Blood Group and Survival in Pancreatic Cancer?
Kos F. T., Civelek B., Seker M. M., ARIK Z., AKSOY S., Uncu D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.13, sa.12, ss.6151-6153, 2012 (SCI-Expanded, Scopus)
2010
201044. Breast Cancer in a Patient with Agnogenic Myeloid Metaplasia
ARIK Z., OZKAN C., Ozdemir E., ALTUNDAG K.
SOUTHERN MEDICAL JOURNAL
, cilt.103, sa.10, ss.1075-1076, 2010 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG)
Akyildiz A., GÜLTEKİN M., Yigit E., Demir E., Ismayilov R., AHMED M. A., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2019
20192. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2019
20193. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2019
20194. Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?
Lacin S., Tasar G. E., Usubutun A., Arik Z., Karakas Y., Yuce D., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
2017
20175. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.
22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2015
20156. Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.
Arik Z., Dizdar O., Yildirim M. E., Ozgu E., Oz M., Terzioglu S. G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2014
20147. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
20148. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience
Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.
Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri)
2013
20139. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201310. Clinicopathologic characteristics of pure papillary breast carcinoma
Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201311. Inflammatory markers in metastatic breast cancer.
Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2012
201212. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.
Arik Z., Aksoy S., Sendur M. A. N., Yaman S., Altundag K.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201213. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.
Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201214. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?
Yaman S., Aksoy S., Sendur M. A. N., Arik Z., Ozdemir N., Zengin N., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201215. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use
Aksoy S., Sendur M. A. N., Yaman S., Arik Z., Ozdemir N., Zengin N., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
Kitaplar
2018
20181. Kastrasyona dirençli prostat kanseri tedavisi
ERMAN M., ARIK Z.
Üroonkoloji Kitabı, , Editör, Nobel, 2018